Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Sodium-glucose cotransporter 2 inhibition, towards an indication to treat diabetic kidney disease

  • Górriz, Jose Luis|||0000-0002-1134-9051
  • Navarro-González, Juan F.|||0000-0002-5015-7474
  • Ortiz, Alberto|||0000-0002-9805-9523
  • Vergara, Ander|||0000-0003-1926-0147
  • Núñez, Julio|||0000-0003-1672-7119
  • Jacobs-Cachá, Conxita|||0000-0003-2518-7847
  • Martínez-Castelao, Alberto
  • Soler, María José|||0000-0003-3621-0766
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have clearly demonstrated their beneficial effect in diabetic kidney disease (DKD) on top of the standard of care [blood glucose control, renin-angiotensin system blockade, smoking cessation and blood pressure (BP) control], even in patients with overt DKD. However, the indication of this drug class is still blood glucose lowering in type 2 diabetic patients with estimated glomerular filtration rate >45 mL/min/1.73 m 2. Based on the new evidence, several scientific societies have emphasized the preferential prescription of SGLT2i for patients at risk of heart failure or kidney disease, but still within the limits set by health authorities. A rapid positioning of both the European Medicines Agency and the US Food and Drug Administration will allow patients with overt DKD to benefit from SGLT2i. Clinical experience suggests that SGLT2i safety management may in part mirror renin-angiotensin blockade safety management in patients with overt DKD. This review focuses on the rationale for an indication of SGTL2i in DKD. We further propose clinical steps for maximizing the safety of SGLT2i in DKD patients on other antidiabetic, BP or diuretic medication.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Podocyturia, why it may have added value in rare diseases

  • Sánchez Niño, María Dolores
  • Pérez-Gómez, Maria Vanessa|||0000-0003-4558-5236
  • Valiño-Rivas, Lara
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Ortiz, Alberto|||0000-0002-9805-9523
Fabry disease is an inherited lysosomal disease in which defects in the GLA gene lead to α-galactosidase-A deficiency, and accumulation of glycosphingolipids, including lyso-Gb3, a podocyte stressor. Therapy is available as enzyme replacement therapy and, for some patients, the chaperone migalastat. A key decision is when to start therapy, given its costs and potential impact on some aspects of quality of life. The decision is especially difficult in otherwise asymptomatic patients. A delayed start of therapy may allow kidney injury to progress subclinically up to the development of irreversible lesions. Non-invasive tools to monitor subclinical kidney injury are needed. One such tool may be assessment of podocyturia. In this issue of CKJ, [Trimarchi H, Canzonieri R, Costales-Collaguazo C et al. Early decrease in the podocalyxin to synaptopodin ratio in urinary Fabry podocytes. Clin Kidney J 2019; doi.org/10.1093/ckj/sfy053] report on podocyturia assessment in Fabry nephropathy. Specifically, they report that podocalyxin may be lost from detached urinary podocytes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

MYH9-related disease, it does exist, may be more frequent than you think and requires specific therapy

  • Fernandez-Prado, Raul
  • Carriazo-Julio, Sol Maria
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Ortiz, Alberto|||0000-0002-9805-9523
  • Pérez-Gómez, Maria Vanessa|||0000-0003-4558-5236
In this issue of ckj, Tabibzadeh et al. report one of the largest series of patients with MYH9 mutations and kidney disease. The cardinal manifestation of MYH9-related disease is thrombocytopenia with giant platelets. The population frequency of pathogenic MYH9 mutations may be at least 1 in 20 000. The literature abounds in misdiagnosed cases treated for idiopathic thrombocytopenic purpura with immune suppressants and even splenectomy. Additional manifestations include neurosensorial deafness and proteinuric and hematuric progressive kidney disease (at some point, it was called Alport syndrome with macrothrombocytopenia), leucocyte inclusions, cataracts and liver enzyme abnormalities, resulting in different names for different manifestation combinations (MATINS, May-Hegglin anomaly, Fechtner, Epstein and Sebastian syndromes, and deafness AD 17). The penetrance and severity of kidney disease are very variable, which may obscure the autosomal dominant inheritance. A correct diagnosis will both preclude unnecessary and potentially dangerous therapeutic interventions and allow genetic counselling and adequate treatment. Morphological erythrocyte, granulocyte and platelet abnormalities may allow the future development of high-throughput screening techniques adapted to clinical peripheral blood flow cytometers.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Podocyte and tubular involvement in AngioJet-induced kidney injury

  • Esteras, Raquel
  • Cannata-Ortiz, Pablo
  • del Palacio-Tamarit, Marta
  • Guerrero-Hue, Melania
  • García-Caballero, Cristina
  • Egido, Jesús
  • Gimeno Beltran, Javier|||0000-0001-6085-5228
  • Ortiz, Alberto|||0000-0002-9805-9523
  • Gracia-Iguacel, Carolina
  • Moreno Gutiérrez, Juan Antonio|||0000-0002-7468-2871
The AngioJet technique combines localized thrombolysis and percutaneous mechanical thrombectomy (PMT). However, PMT may cause acute kidney injury (AKI), which has been ascribed to severe mechanical haemolysis, although no renal biopsies have been reported. We now report the first renal biopsy in a patient with AKI following PMT. There is histological evidence of haemoglobin (Hb)-induced tubular injury and podocyte stress characterized by intracellular Hb and staining for ferritin and hemo-oxygenase-1, suggestive of an adaptive response to oxidative stress. This confirms that Hb is involved in kidney cell injury and supports the existence of several different kidney cellular targets.